Summary by Futu AI
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 36,319 Class A shares on 03/06/2024, as per the latest filing. The shares, valued at approximately $430,671.77, were acquired through stock option exercises on various dates, with the most recent acquisition on 03/06/2024. Gibson's transactions over the past few months have involved the sale of 163,954 shares, generating gross proceeds of around $1,423,774.95. The upcoming sale is part of a plan adopted on 12/15/2022.